

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application No. 10/586,166

Confirmation No. 5632

Applicant: DeFrees et al.

Filed: July 23, 2008

TC/AU: 1623

Examiner: Scarlett Y. Goon

Docket No.: 705742 (Client Reference No. NEO00298)

Customer No.: 23460

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**REVOCATION OF
FORMER POWERS OF ATTORNEY AND
NEW POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST**

Sir:

Novo Nordisk A/S (hereinafter the "assignee") is the assignee of record of the entire interest of the above-identified U.S. patent application, and has a place of business at Bagsvaerd, Denmark.

Pursuant to 37 CFR 3.73(b), the undersigned has reviewed evidentiary documents establishing a chain of title from the inventor(s) to the assignee and, to the best of the undersigned's knowledge and belief, certifies that title is in the assignee. The chain of title from the inventor(s) to the assignee was recorded in the U.S. Patent and Trademark Office on June 13, 2008 at Reel 021094, Frame No. 0399, and on February 23, 2009 at Reel 022441, Frame No. 0937.

The assignee hereby revokes all previously given powers of attorney and appoints the following as its attorneys to prosecute and transact all business in the U.S. Patent and Trademark Office connected with the application, including receiving all documents issued by the U.S. Patent and Trademark Office based thereon; filing continuation, continuation-in-part and divisional applications based thereon; paying any and all fees, including maintenance fees for any resulting patent; and filing for reissues and extensions and

requesting reexamination of any resulting patent, with all such powers to be exercised separately or collectively:


Customer Number

23460

The assignee requests that correspondence concerning this application be directed to the above-mentioned Customer Number.

The assignee also requests that all telephone calls be directed to John Kilyk, Jr., of Leydig, Voit & Mayer, Ltd. at (312) 616-5600.

Date: 23rd Nov 2009



Lars Kellberg
Corporate Vice President, Corporate Patents
Novo Nordisk A/S